Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052099 | 0.82 | HRH3 (0.40) | PPARGFFAR1CYP3A4PPARAHRH3 | |
| SCHEMBL4283015 | 0.78 | PPARG (0.63) | PPARGCYP3A4PPARA | |
| SCHEMBL170065 | 0.78 | PPARG (0.63) | PPARGCYP3A4PPARA | |
| SCHEMBL12515224 | 0.78 | FFAR1 (0.69) | PPARGFFAR1CYP3A4RXRAPPARA | |
| SCHEMBL8458527 | 0.77 | FFAR1 (0.54) | PPARGFFAR1CYP3A4RXRAHRH3 | |
| SCHEMBL6356578 | 0.77 | PPARG (0.68) | PPARGFFAR1PPARAHRH3 | |
| SCHEMBL1072226 | 0.77 | FFAR1 (0.77) | PPARGFFAR1CYP3A4PPARAHRH3 | |
| SCHEMBL5935692 | 0.76 | PPARG (0.69) | PPARGFFAR1PPARAHRH3 | |
| SCHEMBL8304608 | 0.75 | PPARG (0.55) | PPARGFFAR1RXRAPPARAHRH3 | |
| SCHEMBL8390608 | 0.75 | PPARG (0.66) | PPARGFFAR1RXRAPPARAHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1047423-B1 | NOVEL APOPTOSIS INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2006-05-10 | — | — | EP | disclosed |
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-07-04 | — | — | US | disclosed |
| US-6399639-B1 | ADMINISTERING A 2,4-THIADIAZOLIDINEDIONE COMPOUND | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| US-6087384-A | TREATING PROPHYLAXIS AND TREATMENT OF A DISEASE ASSOCIATE WITH DEATH OF CELLS CAUSED BY VIRAL DISEASES, MYELODYSPLASIS, NEURODEGENERATIVE, ISCHEMIC AND HEPATIC DISEASES WITH A COMPOUND HAVING AN INSULIN SENSITIVITY ENHANCING ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086883-A1 | Compound, such as pioglitazone, having an insulin sensitivity enhancing activity for the prophylaxis or treatment of a disease mediated by promotion of apoptosis, such as neurodegenerative disease | IRS1, IAPP, AIFM1 | PPARG 51/4885FFAR1 340/4885CYP3A4 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.